MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

Home・Aandelen Lijst・uniQure NV

uniQure NV

Gesloten

8.94 -7.17

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.68

Max

9.63

Belangrijke statistieken
By Trading Economics
Inkomsten	-29M -73M
Verkoop	2.9M 5.2M
EPS	-1.442
Winstmarge	-1,403.199
Werknemers	209
EBITDA	-28M -53M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+272.21% upside

Dividenden
By Dow Jones
Volgende Winsten	6 mei 2025

Marktinformatie
By TradingEconomics
Marktkapitalisatie	84M 674M
Vorige openingsprijs	16.11
Vorige sluitingsprijs	8.94

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

9.7 / 10.61 Steun & Weerstand

uniQure NV Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 dec 2024, 15:18 UTC

Belangrijke Marktbewegers

UniQure Shares Double After FDA Agreement on Pathway for Huntington's Disease Treatment

Peer Vergelijking

Prijswijziging

uniQure NV Prognose

Koersdoel

By TipRanks

272.21% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 36.29 USD 272.21%

Hoogste 70 USD

Laagste 18 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor uniQure NV - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan uniQure NV - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

9.7 / 10.61Steun & Weerstand

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over uniQure NV

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.